Table 2.

Association of CFU-F presence with alloSCT-related factors and with remission status at time of BM aspirate in the cohort of patients receiving alloSCT

CFU-F present
N (%)
No CFU-F present
N (%)
P value
Disease status at time of alloSCT   .50 
CR 58 (42.3) 23 (47.9)  
Non CR 79 (57.7) 25 (52.1)  
Conditioning regimen   .22 
MAC 22 (15.8) 12 (23.5)  
RIC or NMA 117 (84.2) 39 (76.5)  
Use of ATG   .07 
Yes 116 (84.1) 37 (72.5)  
No 22 (15.9) 14 (27.5)  
GvHD-prophylaxis   .21 
CNI + MMF 104 (78.8) 35 (70.0)  
CNI + MTx 28 (21.2) 15 (30.0)  
Remission at BM aspirate   .76 
CR 120 (84.5) 43 (82.7)  
Non CR 22 (15.5) 9 (17.3)  
Chimerism at BM aspirate   .047 
100% donor 104 (80.0) 28 (65.1)  
Persisting recipient fraction 26 (20.0) 15 (34.9)  
CFU-F present
N (%)
No CFU-F present
N (%)
P value
Disease status at time of alloSCT   .50 
CR 58 (42.3) 23 (47.9)  
Non CR 79 (57.7) 25 (52.1)  
Conditioning regimen   .22 
MAC 22 (15.8) 12 (23.5)  
RIC or NMA 117 (84.2) 39 (76.5)  
Use of ATG   .07 
Yes 116 (84.1) 37 (72.5)  
No 22 (15.9) 14 (27.5)  
GvHD-prophylaxis   .21 
CNI + MMF 104 (78.8) 35 (70.0)  
CNI + MTx 28 (21.2) 15 (30.0)  
Remission at BM aspirate   .76 
CR 120 (84.5) 43 (82.7)  
Non CR 22 (15.5) 9 (17.3)  
Chimerism at BM aspirate   .047 
100% donor 104 (80.0) 28 (65.1)  
Persisting recipient fraction 26 (20.0) 15 (34.9)  

For each patient, only the last available BM aspirate after alloSCT was included to avoid bias of repeated aspirates. Comparison was performed univariately using χ2 test.

ATG, anti-thymocyte globuline; CNI, calcineurin inhibitor (cyclosporine A or tacrolimus); CR, complete remission; MAC, myeloablative conditioning; MMF, mycophenolate; MTx, methotrexate; NMA, nonmyeloablative conditioning; RIC, reduced intensity conditioning.

or Create an Account

Close Modal
Close Modal